Natco Pharma Fact Sheet, Natco Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Natco Pharma Fact Sheet    (NTPH)


New Research: Our #1 Stock Pick Right Now


Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

NATCO PHARMA Price History

Price Rs 924.1
Mkt Cap Rs m 153,531
Vol '000 44.1
P/E X 35.1
P/CF X 21.2
EPS (TTM) Rs 26.3
% ch % -0.3
No. of shares m 166.15
% ch week % -1.0
% ch 1-mth % 0.6
% ch 12-mth % 50.5
52 week H/L Rs 995.1/556.5
(As on May 12, 2021 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NATCO PHARMA Financials

No. of Mths
Year Ending
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
5-Yr Chart
Click to enlarge
NATCO PHARMA EQUITY SHARE DATA
High Rs2,2916248491,080849 
Low Rs656366418671557 
Sales per share (Unadj.) Rs248.4327.8578.9592.1573.8 
Earnings per share (Unadj.) Rs37.643.5138.9188.4176.0 
Diluted earnings per shareRs7.59.129.241.838.7 
Cash flow per share (Unadj.) Rs51.858.2154.5206.3198.2 
Dividends per share (Unadj.) Rs5.001.256.758.256.25 
Adj. dividends per shareRs1.000.261.421.831.37 
Dividend yield (eoy) %0.30.31.10.90.9 
Book value per share (Unadj.) Rs254.6372.8473.8833.6842.7 
Adj. book value per shareRs50.978.199.5185.1185.1 
Shares outstanding (eoy) m33.2334.8334.9036.9036.50 
Bonus/Rights/Conversions  -ISISISBB 
Price / Sales ratio x5.91.51.11.51.2 
Avg P/E ratio x39.211.44.64.64.0 
P/CF ratio (eoy) x28.48.54.14.23.5 
Price / Book Value ratio x5.81.31.31.10.8 
Dividend payout %13.32.94.94.43.6 
Avg Mkt Cap Rs m48,96317,23022,11632,31125,660 
No. of employees `0003.11.34.44.85.0 
Total wages/salary Rs m1,3691,8672,4323,2563,559 
Avg. sales/employee Rs Th2,647.78,462.64,579.94,522.54,225.3 
Avg. wages/employee Rs Th439.31,383.8551.3674.0718.0 
Avg. net profit/employee Rs Th400.81,124.21,099.31,439.01,295.9 
NATCO PHARMA INCOME DATA
Net Sales Rs m8,25311,41620,20221,84820,945 
Other income Rs m1491081394041,302 
Total revenues Rs m8,40211,52420,34122,25222,247 
Gross profit Rs m2,1002,6406,8349,2847,948 
Depreciation Rs m473510544662810 
Interest Rs m317229185154193 
Profit before tax Rs m1,4592,0096,2448,8728,247 
Minority Interest Rs m-44-14000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-1510000 
Tax Rs m154791,3951,9201,823 
Profit after tax Rs m1,2491,5174,8496,9526,424 
Gross profit margin %25.423.133.842.537.9 
Effective tax rate %1.023.922.321.622.1 
Net profit margin %15.113.324.031.830.7 
NATCO PHARMA BALANCE SHEET DATA
Current assets Rs m4,8308,32310,87321,30723,472 
Current liabilities Rs m4,1374,9296,2655,9207,287 
Net working cap to sales %8.429.722.870.477.3 
Current ratio x1.21.71.73.63.2 
Inventory Days Days97114637392 
Debtors Days Days85848610788 
Net fixed assets Rs m8,3899,25311,69314,98618,648 
Share capital Rs m332348349369365 
"Free" reserves Rs m7,94512,37316,14430,35334,525 
Net worth Rs m8,46112,98316,53430,76030,760 
Long term debt Rs m9700000 
Total assets Rs m13,84018,23823,17637,15143,031 
Interest coverage x5.69.834.858.643.7 
Debt to equity ratio x0.10000 
Sales to assets ratio x0.60.60.90.60.5 
Return on assets %11.39.621.719.115.4 
Return on equity %14.811.729.322.620.9 
Return on capital %16.817.138.929.327.4 
Exports to sales %34.727.5000 
Imports to sales %6.510.2000 
Exports (fob) Rs m2,8663,141000 
Imports (cif) Rs m5381,168000 
Fx inflow Rs m3,1563,4576,79310,32211,536 
Fx outflow Rs m9591,6882,2542,9782,939 
Net fx Rs m2,1971,7694,5387,3438,597 
NATCO PHARMA CASH FLOW
From Operations Rs m 927 1,024 3,458 4,636 6,688 
From Investments Rs m -1,148 -1,755 -2,994 -11,155 -6,122 
From Financial Activity Rs m 291 856 -477 6,509 -509 
Net Cashflow Rs m 22 117 -7 -18 66 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 1.5%
Indian inst/Mut Fund 7.8%
FIIs 16.6%
ADR/GDR 0.0%
Free float 26.0%
Shareholders 25,395
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF NATCO House, Road No.2, Banjara Hills, Hyderabad - 500 033
E-MAIL investors@natcopharma.co.in WEB www.natcopharma.co.in
TELEPHONE (040) 2354 7532 FAX (040) 2354 8243
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Venture Capital, 12-10-167, Bharatnagar, Hyderabad-500 018
AUDITOR Walker, Chandiok & Co.
CHM: V. C. Nannapaneni (MD) COMP SEC: M. Adinarayana YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 10 DIV YIELD (%): 0.1

More Pharmaceuticals Company Fact Sheets:   SUN PHARMA  PROCTER & GAMBLE HEALTH  IPCA LABS  VENUS REMEDIES  PFIZER  

Compare NATCO PHARMA With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  IPCA LABS  VENUS REMEDIES  PFIZER  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  




Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Views on news

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners (Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps? (Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA - TEVA PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS